

해외 바이오의약품 임상 현황 ('23년 12월 1주)

한국바이오의약품협회, 2023.12.12.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2023.12.04.~2023.12.10.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 13건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05828511	A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment.	Drug: Linvoseltamab	Regeneron Pharmaceuticals	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05828511
NCT06054776	Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Drug: Acalabrutinib Procedure: Biospecimen Collection Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Procedure: Echocardiography Biological: Glofitamab Procedure: Multigated Acquisition Scan Biological: Obinutuzumab Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06054776
NCT05823480	Magrolimab in Combination With Azacitidine After Allogeneic HCT in Treating Patients With High-Risk AML or MDS	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Azacitidine Procedure: Biospecimen Collection Procedure: Bone Marrow Aspirate Procedure: Bone Marrow Biopsy Procedure: Echocardiography Biological: Magrolimab Procedure: Multigated Acquisition Scan Other: Questionnaire Administration	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05823480
NCT05722327	Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer	Drug: MRTX849 Drug: Irinotecan Drug: Cetuximab	M.D. Anderson Cancer Center Mirati Therapeutics	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05722327
NCT05716009	Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML	Drug: Dose Escalation -tagraxofusp-erzs Drug: Dose Expansion at RP2D - tagraxofusp-erzs	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Stemline Therapeutics, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05716009
NCT04482933	HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma	Drug: Biological G207	Pediatric Brain Tumor Consortium Treovir, LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04482933
NCT06127043	A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)	Drug: Rosnilimab Drug: Placebo	AnaptysBio, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06127043
NCT05682443	ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC	Drug: ONC-392 Drug: Lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV infusion, Q6W for up to 6 doses.	OncoC4, Inc. Prostate Cancer Clinical Trials Consortium	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05682443
NCT06079281	Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa	Drug: ALXN1850 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079281

해외 바이오의약품 임상 현황 ('23년 12월 1주)

한국바이오의약품협회, 2023.12.12.

○ 미국 13건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06034002	A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms	Drug: INCA033989	Incyte Corporation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06034002
NCT06079372	Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa	Drug: ALXN1850 Drug: asfotase alfa	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079372
NCT05997264	Anthrax AV7909 Boost Evaluation Study	Biological: AV7909 Full Dose (0.5 mL) Biological: AV7909 Half Dose (0.25 mL)	Biomedical Advanced Research and Development Authority Rho Federal Systems Division, Inc. ICON plc	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05997264
NCT06090539	A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas	Drug: BMS-986458 Drug: Rituximab	Bristol-Myers Squibb	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06090539

○ 영국 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06079281	Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa	Drug: ALXN1850 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079281
NCT06109779	A Study of Rilvegostomig Plus Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection	Drug: Rilvegostomig Drug: Placebo Drug: Capecitabine Drug: Gemcitabine/Cisplatin Drug: S-1 [Tegafur/Oteracil/gimeracil]	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06109779
NCT06079372	Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa	Drug: ALXN1850 Drug: asfotase alfa	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079372

○ 프랑스 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06150040	Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]	Drug: NP137 Drug: Azacitidine Injection Drug: Venetoclax	Centre Leon Berard NETRIS Pharma	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06150040
NCT06045975	Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation	Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting	Assistance Publique - Hôpital de Paris AstraZeneca	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06045975
NCT06090539	A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas	Drug: BMS-986458 Drug: Rituximab	Bristol-Myers Squibb	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06090539
NCT06079281	Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa	Drug: ALXN1850 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079281
NCT06079372	Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa	Drug: ALXN1850 Drug: asfotase alfa	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079372

해외 바이오의약품 임상 현황 ('23년 12월 1주)

한국바이오의약품협회, 2023.12.12.

○ 독일 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06109779	A Study of Rilvegostomig Plus Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection	Drug: Rilvegostomig Drug: Placebo Drug: Capecitabine Drug: Gemcitabine/Cisplatin Drug: S-1 [Tegafur/Oteracil/gimeracil]	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06109779
NCT06079281	Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa	Drug: ALXN1850 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079281
NCT06079372	Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa	Drug: ALXN1850 Drug: asfotase alfa	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079372

○ 중국 6건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06135168	A Clinical Trail to Compare Pharmacokinetics of Two PEG-rhGH Injections With Different Preparations	Drug: PEG-rhGH with new preparation Drug: PEG-rhGH with present preparation	Changchun GeneScience Pharmaceutical Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06135168
NCT06148649	Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus	Drug: HEC88473, Placebo, Dulaglutide	Dongguan HEC Biopharmaceutical R&D Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06148649
NCT05939167	Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage	Drug: mesenchymal stem cell Other: saline	Cell Energy Life Sciences Group Co. LTD Beijing 302 Hospital Shenzhen Third People's Hospital Fifth Hospital of Shijiazhuang City Beijing YouAn Hospital	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05939167
NCT06157827	A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma	Drug: LBL-024 for Injection Drug: Etoposide Injection Drug: Cisplatin for Injection Drug: Carboplatin Injection	Nanjing Leads Biolabs Co.,Ltd	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06157827
NCT06155396	A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer	Drug: Disitamab Vedotin Drug: Zimberelimab	RemeGen Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06155396
NCT06079281	Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa	Drug: ALXN1850 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079281

○ 일본 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06109779	A Study of Rilvegostomig Plus Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection	Drug: Rilvegostomig Drug: Placebo Drug: Capecitabine Drug: Gemcitabine/Cisplatin Drug: S-1 [Tegafur/Oteracil/gimeracil]	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06109779
NCT06079372	Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa	Drug: ALXN1850 Drug: asfotase alfa	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079372
NCT06079281	Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa	Drug: ALXN1850 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079281